SCHEMBL7140639

SCHEMBL7140639

CCOC(=O)CC(NC(=O)c1cc(NC(=O)c2sc(NC(=N)N)nc2C)ccc1OCCOC)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
NPC1 O15118 5/20 0.40
RAB9A P51151 4/20 0.40
LMNA P02545 2/20 0.40
PKM P14618 1/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
HTT P42858 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
THRB P10828 2/20 0.39
POLB P06746 1/20 0.39
RXFP1 Q9HBX9 2/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143937 0.93 MAPT (0.42) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7143951 0.93 MAPT (0.42) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL7141636 0.92 MAPT (0.42) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL7141644 0.92 MAPT (0.42) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7140503 0.84 ALDH1A1 (0.49) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7147810 0.81 ALDH1A1 (0.44) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7142111 0.79 MEN1 (0.44) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL8067753 0.77 ALDH1A1 (0.56) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7143985 0.77 ALDH1A1 (0.51) MAPTKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL7310694 0.76 NPC1 (0.45) KDM4EALDH1A1SMN1; SMN2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US claimed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 MAPT 86/4885KDM4E 4278/4885ALDH1A1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.